News | July 23, 2010

Point-of-Care Analyzer May Speed ER Cardiac Evaluations

July 23, 2010 – For patients suffering from a heart attack, every minute counts, yet the average time from start of chest pain to receiving emergency room (ER) medical attention is 3.2 hours. The average turn-around time of lab-based test results is 2.8 hours, with the minimum time to detect a heart attack using today’s lab-based immunodiagnostics is 4.5 hours from symptom outset.

When it comes to cardiac events and survival, the key factors for a successful recovery are time to diagnosis, accuracy of diagnosis, and appropriate clinical management. For these reasons point-of-care (POC) testing for chest pain patients may help improve patient survival.

Ontario-based CardioGenics has created improved cardiac diagnostic testing that boasts faster results, better accuracy, at reduced cost to the patient and caregiver. The analyzer offers advantages over existing POC immunoassay technology, which the company compares to the shift from portable CD players to iPods. In six steps, the QL Care Analyzer provides printed medical lab quality results in less than 15 minutes. Capable of delivering test results in the ER, doctor’s office, or EMS vehicle, the single-use cartridge QL Care Analyzer is the size of a portable CD player, features an intuitive user interface touch screen, and is capable of storing patient data for up to 5,000 individuals.

The QL Care Analyzer is being submitted to the U.S. Food and Drug Administration (FDA) this summer for testing of troponin I, a protein that is integral to cardiac muscle and its blood level measures the presence and severity of a heart attack.

CardioGenics believes that the device cartridge can ultimately be adapted to run any number of immunoassay tests. (There are approximately 200 different immunoassays for HIV, cancer, thyroid conditions, etc., that are currently performed by lab-based analyzers).

For more information: www.cardiogenics.com

Related Content

Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init